Melanotan II

Peptide

Compounding status of Melanotan II — FDA 503A bulks-list standing, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on trade-press coverage until the FDA primary record posts.

Current federal standing

Not compoundable under 503A

Melanotan II is not on the 503A Bulks List. FDA has scheduled it for the next Pharmacy Compounding Advisory Committee review — by the end of February 2027 (exact date not yet posted). FDA PCAC ↗

We do not sell, source, or supply Melanotan II. This is a monitoring record from public government sources — not a product, and not advice.

Federal history

No federal status has been published for Melanotan II yet. We’re monitoring the Federal Register and FDA/PCAC; a standing appears here only with its source document.

State overlays

No state-specific position on Melanotan II tracked yet. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.

Track Melanotan II changes

Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.

Get the free Brief →

← All substances · Informational monitoring from public government sources — not legal or medical advice. No efficacy claims.